MCPMod: An R Package for the Design and Analysis of Dose-Finding Studies

In this article the MCPMod package for the R programming environment will be introduced. It implements a recently developed methodology for the design and analysis of dose-response studies that combines aspects of multiple comparison procedures and modeling approaches (Bretz et al. 2005). The MCPMod package provides tools for the analysis of dose finding trials, as well as a variety of tools necessary to plan an experiment to be analyzed using the MCP-Mod methodology.

• Publication year

  2009

• Venue

  Journal of Statistical Software

• Publication date

  2009-02-20

• Fields of study

  Computer Science

• Identifiers
  DOI 10.18637/JSS.V029.I07
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose–Response Studies

  2010cited by this paper
• Optimal Designs for Dose-Finding Studies

  2008cited by this paper
• Dose–Response Studies

  2007cited by this paper
• Analysis of Dose–Response Studies—Modeling Approaches

  2006cited by this paper
• Design and Analysis of Dose-Finding Studies Combining Multiple Comparisons and Modeling Procedures

  2006cited by this paper
• Dose Finding in Drug Development

  2006cited by this paper
• Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies

  2005cited by this paper
• Separable nonlinear least squares: the variable projection method and its applications

  2003cited by this paper
• Comparison of Methods for the Computation of Multivariate t Probabilities

  2002cited by this paper
• Model selection: An integral part of inference

  1997cited by this paper
• Dose response studies. I. Some design considerations.

  1995cited by this paper
• Testing the statistical certainty of a response to increasing doses of a drug.

  1985cited by this paper
• Some design considerations

  1960cited by this paper

• Phase 2 Design Considerations from a Program Perspective

  2026cites this paper
• Comparison of methods for identifying the optimal treatment duration in randomized trials for antibiotics

  2025cites this paper
• Dose–effect relationship of intravenous tranexamic acid on perioperative haemoglobin drop in total hip arthroplasty (PRADO study): study protocol for a randomised, double-blind, placebo-controlled, dose–response study

  2025cites this paper
• Optimal designs for identifying effective doses in drug combination studies

  2025cites this paper
• Overcoming Model Uncertainty — How Equivalence Tests Can Benefit From Model Averaging

  2024cites this paper
• MoS-TEC: A toxicogenomics database based on model selection for time-expression curves

  2024cites this paper
• Comparison of methods for identifying the optimal treatment duration in trials for antibiotics

  2024influential citation
• Simultaneous Inference Using Multiple Marginal Models

  2024cites this paper
• Identification of changes in gene expression

  2024cites this paper
• nlive: an R package to facilitate the application of the sigmoidal and random changepoint mixed models

  2023cites this paper
• Improved inference for MCP‐Mod approach using time‐to‐event endpoints with small sample sizes

  2023cites this paper
• Sample size calculation for multi-arm parallel design with restricted mean survival time

  2023cites this paper
• A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

  2023cites this paper
• nlive: an R Package to facilitate the application of the sigmoidal and random changepoint mixed models

  2023cites this paper
• A Method for Ensuring a Consistent Dose–Response Relationship Between An Entire Population and One Region in Multiregional Dose–Response Studies Using MCP-Mod

  2023influential citation
• DoseFinding-package 3 MCPMod : Performs MCPMod methodology sampSize : General function for sample size calculation

  2023cites this paper
• A comparative study of in vitro dose–response estimation under extreme observations

  2023influential citation
• SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial

  2023cites this paper
• Bayesian MCPMod

  2022cites this paper
• Confirmatory efficacy testing for individual dose–placebo comparisons using serial gatekeeping procedure in dose‐finding trials with multiple comparison procedures–modeling

  2022cites this paper
• Confidence intervals for point‐of‐stabilization of content uniformity

  2022cites this paper
• Model selection characteristics when using MCP‐Mod for dose–response gene expression data

  2022cites this paper
• Comparison of Power of Trend Tests for Toxicological Application Based on Dose–Response Profiles Enumerated Using a Nonparametric Algorithm

  2022cites this paper
• A Comprehensive Toolbox to Facilitate Quantitative Decision Science in Drug Development: A web-based R shiny application GOahead

  2022cites this paper
• A novel model-checking approach for dose-response relationships

  2021cites this paper
• Optimal adaptive allocation using deep reinforcement learning in a dose‐response study

  2021cites this paper
• Choosing Metrics Appropriate for Different Stages of Drug Development

  2021cites this paper
• Utility-Based Dose Selection for Phase II Dose-Finding Studies

  2021cites this paper
• Dose‐Finding

  2021cites this paper
• Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

  2021cites this paper
• Package ‘ DoseFinding ’ June 25 , 2021 Type Package

  2021cites this paper
• An Overview of Phase II Clinical Trial Designs.

  2021cites this paper
• The Tukey trend test: Multiplicity adjustment using multiple marginal models

  2021cites this paper
• Designing Dose–Response Studies with Desired Characteristics

  2021cites this paper
• Package ‘ DoseFinding ’ October 3 , 2021 Type Package

  2021cites this paper
• Sample size re‐estimation in Phase 2 dose‐finding: Conditional power versus Bayesian predictive power

  2020cites this paper
• Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs

  2020cites this paper
• Statistical Data Mining of Clinical Data

  2020cites this paper
• Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials

  2020cites this paper
• Point and interval estimation of the target dose using weighted regression modelling

  2020cites this paper
• BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs

  2020cites this paper
• Robust designs in longitudinal studies accounting for parameter and model uncertainties – application to count data

  2020cites this paper
• Assessing Dunnett and MCP-Mod based approaches in two-stage dose-finding trials

  2019cites this paper
• A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints

  2019cites this paper
• Utility-based optimization of phase II / phase III clinical development

  2019cites this paper
• Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials

  2019cites this paper
• Generalized multiple contrast tests in dose‐response studies

  2019cites this paper
• SamP2CeT: an interactive computer program for sample size and power calculation for two-level cost-effectiveness trials

  2018cites this paper
• Sicegar: R package for sigmoidal and double-sigmoidal curve fitting

  2018cites this paper
• Power and sample size for dose‐finding studies with survival endpoints under model uncertainty

  2018influential citation
• BMA‐Mod: A Bayesian model averaging strategy for determining dose‐response relationships in the presence of model uncertainty

  2018cites this paper
• Key Aspects of Modern, Quantitative Drug Development

  2018cites this paper
• AWARD NUMBER: W81XWH-17-C-0153 TITLE: Developing software for Pharmacodynamics and Bioassay Studies PRINCIPAL INVESTIGATOR: Hua Liang CONTRACTING ORGANIZATION: TCONNEX Inc

  2018cites this paper
• Key Aspects of Modern, Quantitative Drug Development

  2018cites this paper
• Designing Dose-Response Studies with Desired Characteristics

  2017cites this paper
• Identification of the minimum effective dose for normally distributed data using a Bayesian variable selection approach

  2017cites this paper
• A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy

  2017influential citation
• Design of clinical trials involving multiple hypothesis tests with a common control

  2017cites this paper
• Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies

  2017influential citation
• Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

  2017cites this paper
• Data Analysis for Dose-Ranging Trials with Continuous Outcome

  2017cites this paper
• Dose-ranging design and analysis methods to identify the minimum effective dose (MED).

  2017cites this paper
• A Model-Based Meta-Analysis Evaluating Gender Differences on Blood Flow Responses to Brachial Artery Infusions of Acetylcholine, Albuterol, ATP, Bradykinin, Estradiol, Glyceryl Trinitrate, L-NMMA, Nevibolol, Norepinephrine, Sodium Nitroprusside, Substance P, and Verapamil.

  2016cites this paper
• A New Approach to Dose Estimation in Drug Development Based on Maximization of Likelihood of Grouped Data

  2016influential citation
• The influences of nitric oxide, epinephrine, and dopamine on vascular tone: dose-response modeling and simulations.

  2016cites this paper
• Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism using Electrophysiological Neuroimaging.

  2016cites this paper
• Uterotonic agents for caesarean section

  2015influential citation
• Dose-Response Analysis Using R

  2015cites this paper
• Statistical Analysis Plan

  2015cites this paper
• Universitet Dose-response analysis using

  2015cites this paper
• Curve fitting with confidence for preclinical dose-response data

  2015cites this paper
• Testing effect of a drug using multiple nested models for the dose–response

  2015influential citation
• OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

  2015cites this paper
• Identifying a rapid bolus dose of dexmedetomidine (ED50) with acceptable hemodynamic outcomes in children

  2014cites this paper
• Dose–Response Modeling Under Simple Order Restrictions Using Bayesian Variable Selection Methods

  2014cites this paper
• A Review of Available Software and Capabilities for Adaptive Designs

  2014cites this paper
• Adaptive design of clinical trials : understanding the barriers to adoption

  2014cites this paper
• Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives

  2014cites this paper
• Model‐based dose finding under model uncertainty using general parametric models

  2013cites this paper
• Dose-response and finding in phase II clinical studies — MCP-Mod Methodologies

  2013cites this paper
• Development IIS Efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty Request for CHMP Qualification Opinion

  2013influential citation
• Confidence intervals after multiple imputation: combining profile likelihood information from logistic regressions

  2013cites this paper
• Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2 La carbetocine lors d'un accouchement par cesarienne programme ´: une etude randomisee controlee pour determiner la dose efficace, 2 e partie

  2013cites this paper
• ADDPLAN® DF AN ADVANCED TOOL FOR OPTIMIZING DOSE SELECTION IN EXPLORATORY DRUG DEVELOPMENT

  2013cites this paper
• Experimental designs for drug combination studies

  2012cites this paper
• Model-Based Approaches

  2012cites this paper
• Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose, part 2

  2012cites this paper
• Statistical Methods for Microarray Experiments: Analysis Dose-response Studies and Software Development in R

  2011influential citation
• Adaptive Dose-Ranging Studies

  2010cites this paper
• A Simulation Study to Compare New Adaptive Dose–Ranging Designs

  2010cites this paper
• Adaptive designs for dose response studies

  2010cites this paper
• Adaptive dose‐finding: Proof of concept with type I error control

  2010cites this paper
• On Nonparametric Bayesian Analysis under Shape Constraints with Applications in Biostatistics

  2009cites this paper
• Dose Finding – A Challenge in Statistics

  2008influential citation
• Recommendations : Soluble biomarker assessments in clinical trials in osteoarthritis

  year unknowncites this paper